Smartleaf Asset Management LLC Has $666,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Smartleaf Asset Management LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 32.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,105 shares of the company’s stock after purchasing an additional 1,012 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Zoetis were worth $666,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Cantillon Capital Management LLC raised its position in shares of Zoetis by 0.5% during the 4th quarter. Cantillon Capital Management LLC now owns 1,293,251 shares of the company’s stock valued at $210,709,000 after acquiring an additional 6,920 shares during the last quarter. Middleton & Co. Inc. MA boosted its position in shares of Zoetis by 3.7% in the 4th quarter. Middleton & Co. Inc. MA now owns 12,757 shares of the company’s stock worth $2,078,000 after purchasing an additional 450 shares during the last quarter. Jacobi Capital Management LLC grew its stake in shares of Zoetis by 2.3% during the fourth quarter. Jacobi Capital Management LLC now owns 8,978 shares of the company’s stock worth $1,463,000 after purchasing an additional 203 shares during the period. Richard W. Paul & Associates LLC increased its holdings in Zoetis by 5.9% in the fourth quarter. Richard W. Paul & Associates LLC now owns 7,108 shares of the company’s stock valued at $1,158,000 after purchasing an additional 398 shares during the last quarter. Finally, Metis Global Partners LLC lifted its stake in Zoetis by 3.8% in the fourth quarter. Metis Global Partners LLC now owns 33,418 shares of the company’s stock valued at $5,445,000 after buying an additional 1,231 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of several analyst reports. Barclays boosted their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. StockNews.com cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average price target of $215.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Shares of NYSE ZTS opened at $170.47 on Tuesday. The company has a fifty day moving average price of $166.42 and a 200 day moving average price of $177.16. The firm has a market cap of $76.34 billion, a PE ratio of 31.16, a PEG ratio of 2.78 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.